Related Experiment Videos
Leishmaniasis in HIV infection.
1Internal Medicine Department, Hospital de la Santa Creu i Sant Pau. Av. Sant Antoni Maria Claret 167, 08025 Barcelona. Catalonia. Spain. 34120rpd@comb.es
Journal of Postgraduate Medicine
|July 17, 2003
Summary
HIV and leishmaniasis co-infection presents unique challenges. Highly Active Antiretroviral Therapy (HAART) impacts leishmaniasis incidence and transmission in co-infected individuals.
Area of Science:
- Infectious Diseases
- Immunology
- Public Health
Background:
- Leishmaniasis is a parasitic disease, while HIV is a viral infection.
- Co-infection with HIV and Leishmania parasites significantly alters disease presentation and progression.
- Understanding the interplay between these infections is crucial for effective management.
Purpose of the Study:
- To review the specific aspects of leishmaniasis in the context of HIV infection.
- To analyze the influence of Highly Active Antiretroviral Therapy (HAART) on HIV/Leishmania co-infection.
- To present comprehensive information on epidemiology, pathogenesis, clinical presentation, and treatment.
Main Methods:
- Literature review of studies identified through PubMed searches.
- Inclusion of articles from reference lists of reviewed papers.
- Inclusion of data from authors' personal archives.
Main Results:
- Epidemiological data on HIV/Leishmania co-infection is discussed.
- The impact of HAART on leishmaniasis incidence and transmission is examined.
- Microbiological, pathogenic, clinical, and treatment aspects are presented.
Conclusions:
- HIV significantly impacts leishmaniasis, leading to more severe and disseminated forms.
- HAART has a crucial role in modulating the incidence and transmission of leishmaniasis in HIV-infected individuals.
- Integrated management strategies are essential for addressing this co-infection effectively.